Use of a vector expressing DNA polymerase β as medicine
AssigneeCentre National de la Recherche Scientifique (CNRS)
InventorsChristophe Cazaux, Gérard Jean Tiraby, Pascal Fons, Jean-Sébastien Hoffmann
Life of this patent
Estimating the term…
Abstract
The invention concerns the use of a vector expressing DNA polymerase β for the treatment of cancer or viral diseases such as AIDS.
Claims13
An expression vector comprising a polynucleotide sequence encoding DNA polymerase β and a polynucleotide sequence encoding thymidine kinase or thymidilate kinase, wherein said polynucleotide sequences are under the control of an expression system which is effective in expressing said polymerase β in a cell.
A pharmaceutical composition comprising an expression vector comprising a polynucleotide sequence encoding DNA polymerase β and at least one nucleoside analog, wherein said polynucleotide sequence is under the control of an expression system which is effective in expressing said DNA polymerase β and induces overproduction of said DNA polymerase β in tumor cells or cells infected by a virus.
A method for enhancing the capability of a tumor cell in incorporating a nucleoside analog having antiviral or antitumor activity into DNA of said cell, comprising introducing directly into said cell with an expression vector, thereby inducing overproduction of DNA polymerase β in said cell, wherein said expression vector comprises a polynucleotide sequence encoding DNA polymerase β under the control of an expression system which is effective in expressing said DNA polymerase β and induces overproduction of said DNA polymerase β in said tumor cell.
Dependencies are inferred from the claim text.